Ch 6: RELATED ASPECTS OF COMPANY ACCOUNTS — V2: Applied Practical Scenarios & Financial Computations
CS Executive
📚 Corporate Accounting & Financial Management
📖 Ch.6 — RELATED ASPECTS OF COMPANY ACCOUNTS
📘 V2: Study Material & Test Yourself
⚡ Free Mode (Answers Locked)
⏱ Duration: 90 Mins
🎯 Total Marks: 50
Passed at: 20 Marks
Max Attempts: 10
⚖️ Statutory Applicability: Applicable for ICSI CS Executive Examinations (December 2026 Attempt - Syllabus 2022)
Exhaustive ICSI CS Executive Test Series with 4-Tier Rubrics, Statutory Analysis, and Real-world Corporate Problem Scenarios.
📑 Exam Questions
5 Questions • Total 50 MarksQuestion 1: PRACTICAL NUMERICAL: Accounting for Employee Stock Option Plans (ESOP) - Employee Compensation Expense amortization over vesting period.
10 Marks
📌 Companies Act, 2013 Section 62(1)(b) & Rule 12 of Companies (Share Capital and Debentures) Rules, 2014 read with Guidance Note on Accounting for Employee Share-based Payments.
Sahyadri Infotech Limited established an Employee Stock Option Plan (ESOP) granting 10,000 options to its eligible employees on 1st April 2021 at an exercise price of ₹40 per share, when the market price (fair value) of the share was ₹120. The vesting period is 3 years. On 31st March 2022, 400 options were lapsed due to resignation of employees. On 31st March 2023, the company revised its estimate of total employees completing the vesting period, and expected total lapses to be 1,200 options over the 3-year vesting period. On 31st March 2024, the actual total lapses at the end of the vesting period were 1,000 options. Out of the vested options, 8,500 options were exercised on 15th April 2024, and the remaining vested options lapsed unexercised. Pass necessary Journal Entries (with detailed narrations) for the financial years 2021-22, 2022-23, 2023-24, and 2024-25, and prepare the ESOP Outstanding Account and Employee Compensation Expense Account in the books of Sahyadri Infotech Limited.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 2: PRACTICAL NUMERICAL: Buy-back of shares accounting - Journal entries, utilization of securities premium, transfer to Capital Redemption Reserve (CRR).
10 Marks
📌 Companies (Amendment) Act and SEBI (Buy-Back of Securities) Regulations, 2018 compliance.
M/s Kalinga Technologies Limited provides the following extract of its Balance Sheet as at 31st March, 2024. The company proposes to buy-back 20% of its equity share capital at a price of ₹ 25 per share. Pass necessary Journal Entries in the books of the company, show the transfer to Capital Redemption Reserve (CRR) as per statutory requirements under the Companies Act, 2013, and prepare the Balance Sheet extract after the buy-back.
| Liabilities | Amount (₹) | Assets | Amount (₹) |
| :--- | :--- | :--- | :--- |
| Equity Share Capital (Equity Shares of ₹ 10 each, fully paid) | 50,00,000 | Property, Plant & Equipment | 85,00,000 |
| Securities Premium Account | 15,00,000 | Current Assets | 40,00,000 |
| General Reserve | 25,00,000 | | |
| Profit & Loss Account (Credit Balance) | 20,00,000 | | |
| 10% Debentures | 15,00,000 | | |
| Current Liabilities | 0,00,000 | | |
| **Total** | **1,25,00,000** | **Total** | **1,25,00,000**
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 3: PRACTICAL NUMERICAL: Issue of Bonus shares and Rights shares accounting journal entries.
10 Marks
📌 Companies Act, 2013 Section 63 & 62 compliance, including restriction on revaluation reserves capitalization.
M/s Kalinga Dynamics Limited presents the following extract of its Balance Sheet as at 31st March, 2023. The Board of Directors decides to capitalize its reserves by issuing bonus shares and subsequently offering a rights issue to existing shareholders. You are required to pass necessary journal entries in the books of the company and prepare the revised Balance Sheet extract after giving effect to both transactions.
### Table 1: Balance Sheet Extract as at 31st March, 2023
| Particulars | Note No. | Amount (₹)
| :--- | :---: | :--- |
| **I. EQUITY AND LIABILITIES** | | |
| **(1) Shareholder's Funds** | | |
| (a) Share Capital | 1 | 5,00,00,000 |
| (b) Reserves and Surplus | 2 | 3,80,00,000 |
| **TOTAL** | | **8,80,00,000** |
### Table 2: Notes to Accounts Details
| Note No. | Particulars | Amount (₹) |
| :---: | :--- | :--- |
| **1** | **Share Capital:** | |
| | 50,00,000 Equity Shares of ₹10 each, fully paid-up | 5,00,00,000 |
| **2** | **Reserves and Surplus:** | |
| | Capital Redemption Reserve (CRR) | 40,00,000 |
| | Securities Premium Account | 90,00,000 |
| | General Reserve | 1,50,00,000 |
| | Surplus i.e. Balance in Statement of Profit and Loss | 1,00,00,000 |
| | **Total Reserves and Surplus** | **3,80,00,000** |
**Additional Corporate Actions:**
1. **Bonus Issue:** On 1st May, 2023, the company resolves to capitalize its reserves by issuing bonus shares in the ratio of 1 fully paid-up equity share of ₹10 each for every 5 existing equity shares held. As per Articles of Association, capital redemption reserve and securities premium must be utilized first before general reserve and statement of profit and loss.
2. **Rights Issue:** Immediately following the bonus issue, on 1st June, 2023, the company makes a rights issue of 1 equity share for every 4 shares held after the bonus issue, at a price of ₹15 per share (face value ₹10, premium ₹5 per share). The entire amount is payable with the application. The issue is fully subscribed and all money is received.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 4: Comprehensive review of key exam provisions of RELATED ASPECTS OF COMPANY ACCOUNTS (Part 4)
10 Marks
📌 Companies (Amendment) Act and NCLT (Reduction of Share Capital) Rules, read with SEBI ICDR and Buy-Back Regulations
M/s Kalinga Pharma Limited is undertaking a comprehensive corporate restructuring and capital reduction exercise under Section 66 of the Companies Act, 2013, alongside buyback of equity shares pursuant to Section 68. The Board of Directors has placed the following summarized pre-scheme Balance Sheet extract as at 31st March 2024 before you, as the Chief Senior Examiner and Corporate Secretarial Consultant, for formulating the necessary accounting treatments, journal entries, and the post-scheme financial structure.
Table 1: Pre-Scheme Balance Sheet Extract of M/s Kalinga Pharma Limited as at 31st March 2024
| Liabilities & Equity | Amount (₹ in Lakhs) | Assets | Amount (₹ in Lakhs) |
|---|---|---|---|
| Equity Share Capital (₹10 per share, fully paid) | 5,000.00 | Property, Plant & Equipment (At Cost) | 7,500.00 |
| 8% Preference Share Capital (₹100 per share) | 2,000.00 | Intangible Assets (Goodwill & Patents) | 1,200.00 |
| Securities Premium Account | 1,500.00 | Non-Current Investments | 800.00 |
| General Reserve | 1,000.00 | Inventories | 1,500.00 |
| Profit & Loss Account (Debit Balance) | (1,800.00) | Trade Receivables | 2,200.00 |
| 10% Debentures (Secured) | 3,000.00 | Cash and Cash Equivalents | 800.00 |
| Trade Payables | 1,200.00 | Miscellaneous Expenditure (Unwritten) | 500.00 |
| Short-term Provisions | 400.00 | | |
| Total | 14,500.00 | Total | 14,500.00 |
Additional Information / Restructuring Scheme Terms:
1. Preference Dividend Arrears: Preference dividends are in arrears for the last 2 years. The preference shareholders agree to waive 50% of the arrears, and for the remaining 50%, equity shares of ₹10 each fully paid are to be issued.
2. Capital Reduction (Equity): Equity share capital is to be reduced by 60% in face value (i.e., reduced from ₹10 to ₹4 per share), and the reduced shares are to be consolidated back to ₹10 per share (i.e., every 2.5 shares of ₹4 each combined into 1 share of ₹10 each).
3. Asset Impairment & Write-off: Intangible assets, miscellaneous expenditure, and the debit balance of Profit & Loss Account are to be completely written off. Property, Plant & Equipment is to be depreciated/written down by 20%. Inventories are to be revalued at ₹1,200 Lakhs, and Trade Receivables are subject to a provision for doubtful debts of ₹200 Lakhs.
4. Debentureholder Settlement: 25% of the 10% Debentures are settled by issuing equity shares of ₹10 each at par against surrender of debenture certificates.
5. Buyback of Shares: Immediately following the capital reduction, the company proposes to buy back 20% of its newly constituted equity shares out of free reserves/securities premium at a price of ₹12 per share.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Question 5: Comprehensive review of key exam provisions of RELATED ASPECTS OF COMPANY ACCOUNTS (Part 5)
10 Marks
📌 Companies (Amendment) Act and relevant National Financial Reporting Authority (NFRA) notifications applied.
M/s Kalinga Pharma Ltd. presents its trial balance and financial data as on 31st March 2024. The Board of Directors seeks computation of various adjustments relating to redemption of preference shares, issue of bonus shares, managerial remuneration under Section 197 read with Schedule V of the Companies Act, 2013, and final transfer to reserves. Prepare the necessary Journal Entries, statement of calculation of Managerial Remuneration, and the revised Balance Sheet extracts as per Schedule III.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Advertisement